Cure My Disease

Don't miss your cure!

 Log in / Sign up

Japanese study checks safety of gaucher drug VPRIV in Real-World use

NCT ID NCT03625882

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Japan looked at the safety and effectiveness of the drug VPRIV (velaglucerase alfa) in 63 people with Gaucher disease. Participants were either new to treatment or switching from another Gaucher therapy. The main goal was to track side effects and serious side effects, while also measuring changes in hemoglobin levels. Because this is an observational survey, it helps confirm how the drug works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
velaglucerase alfa (VPRIV)
What this could lead to
If results are positive, this could confirm that VPRIV is a safe and effective option for managing Gaucher disease in Japanese patients.
What could go wrong
This is an observational survey, not a controlled trial, so it cannot prove cause and effect. The small size (63 people) and single-country setting may limit how well the findings apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gaucher disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GAUCHER DISEASE

Contacts and locations

Locations

  • Chiba

    Chiba, 266-0007, Japan

  • Fukuyama

    Fukuyama, Hiroshima, 721-0927, Japan

  • Gifu

    Gifu, 500-8212, Japan

  • Hamamatsu

    Hamamatsu, Shizuoka, 431-3125, Japan

  • Hamamatsu

    Hamamatsu, Shizuoka, 434-8511, Japan

  • Higashihiroshima

    Higashihiroshima, Hiroshima, 739-0041, Japan

  • Hiroshima

    Hiroshima, 730-0046, Japan

  • Hiroshima

    Hiroshima, 734-0037, Japan

  • Iwata

    Iwata, Shizuoka, 438-0002, Japan

  • Kagoshima

    Kagoshima, 892-0853, Japan

  • Kawagoe

    Kawagoe, Saitama, 350-8550, Japan

  • Kitakyushu

    Kitakyushu, Fukuoka, 802-0803, Japan

  • Konan

    Kōnan, Aichi-ken, 483-8704, Japan

  • Kumamoto

    Kumamoto, 860-8556, Japan

  • Kurume

    Kurume, Fukuoka, 830-0011, Japan

  • Kyoto

    Kyoto, 606-8507, Japan

  • Matsue

    Matsue, Shimane, 690-0864, Japan

  • Minato

    Minato, Tokyo, 105-8471, Japan

  • Moriyama

    Moriyama, Shiga, 524-0022, Japan

  • Nagoya

    Nagoya, Aichi-ken, 453-0801, Japan

  • Obihiro

    Obihiro, Hokkaido, 080-0016, Japan

  • Okayama

    Okayama, 701-1192, Japan

  • Osaka

    Osaka, 534-0021, Japan

  • Osaka

    Osaka, 545-8586, Japan

  • Osaka

    Osaka, 553-0003, Japan

  • Otsu

    Ōtsu, Shiga, 520-2192, Japan

  • Sagamihara

    Sagamihara, Kanagawa, 252-0375, Japan

  • Saitama

    Saitama, 339-8551, Japan

  • Sendai

    Sendai, Miyagi, 980-8574, Japan

  • Shizuoka

    Shizuoka, 420-8688, Japan

  • Suita

    Suita, Osaka, 565-0871, Japan

  • Sumida-ku

    Sumida-ku, Tokyo, 130-0005, Japan

  • Tokorozawa

    Tokorozawa, Saitama, 359-8513, Japan

  • Tondabayashi

    Tondabayashi, Osaka, 584-0000, Japan

  • Yonago

    Yonago, Tottori, 683-8504, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.